These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 17127391

  • 1. Myocardial extracellular matrix remodeling in ischemic heart failure.
    Gallagher GL, Jackson CJ, Hunyor SN.
    Front Biosci; 2007 Jan 01; 12():1410-9. PubMed ID: 17127391
    [Abstract] [Full Text] [Related]

  • 2. MMP induction and inhibition in myocardial infarction.
    Lindsey ML.
    Heart Fail Rev; 2004 Jan 01; 9(1):7-19. PubMed ID: 14739764
    [Abstract] [Full Text] [Related]

  • 3. Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling.
    Lindsey ML, Iyer RP, Jung M, DeLeon-Pennell KY, Ma Y.
    J Mol Cell Cardiol; 2016 Feb 01; 91():134-40. PubMed ID: 26721597
    [Abstract] [Full Text] [Related]

  • 4. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation.
    Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, Oudit GY, Kassiri Z.
    Circ Res; 2010 Mar 05; 106(4):796-808. PubMed ID: 20056917
    [Abstract] [Full Text] [Related]

  • 5. Myocardial overexpression of TIMP3 after myocardial infarction exerts beneficial effects by promoting angiogenesis and suppressing early proteolysis.
    Takawale A, Zhang P, Azad A, Wang W, Wang X, Murray AG, Kassiri Z.
    Am J Physiol Heart Circ Physiol; 2017 Aug 01; 313(2):H224-H236. PubMed ID: 28550172
    [Abstract] [Full Text] [Related]

  • 6. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
    Spinale FG, Coker ML, Bond BR, Zellner JL.
    Cardiovasc Res; 2000 May 01; 46(2):225-38. PubMed ID: 10773226
    [Abstract] [Full Text] [Related]

  • 7. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.
    Vanhoutte D, Schellings M, Pinto Y, Heymans S.
    Cardiovasc Res; 2006 Feb 15; 69(3):604-13. PubMed ID: 16360129
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.
    Spinale FG.
    Physiol Rev; 2007 Oct 15; 87(4):1285-342. PubMed ID: 17928585
    [Abstract] [Full Text] [Related]

  • 10. Matrix Metalloproteinases in Myocardial Infarction and Heart Failure.
    DeLeon-Pennell KY, Meschiari CA, Jung M, Lindsey ML.
    Prog Mol Biol Transl Sci; 2017 Oct 15; 147():75-100. PubMed ID: 28413032
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.
    Lindsey ML, Zamilpa R.
    Cardiovasc Ther; 2012 Feb 15; 30(1):31-41. PubMed ID: 20645986
    [Abstract] [Full Text] [Related]

  • 13. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.
    Peterson JT, Li H, Dillon L, Bryant JW.
    Cardiovasc Res; 2000 May 15; 46(2):307-15. PubMed ID: 10773235
    [Abstract] [Full Text] [Related]

  • 14. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs.
    Etoh T, Joffs C, Deschamps AM, Davis J, Dowdy K, Hendrick J, Baicu S, Mukherjee R, Manhaini M, Spinale FG.
    Am J Physiol Heart Circ Physiol; 2001 Sep 15; 281(3):H987-94. PubMed ID: 11514263
    [Abstract] [Full Text] [Related]

  • 15. ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat.
    Podesser BK, Siwik DA, Eberli FR, Sam F, Ngoy S, Lambert J, Ngo K, Apstein CS, Colucci WS.
    Am J Physiol Heart Circ Physiol; 2001 Mar 15; 280(3):H984-91. PubMed ID: 11179039
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction.
    Mani SK, Kern CB, Kimbrough D, Addy B, Kasiganesan H, Rivers WT, Patel RK, Chou JC, Spinale FG, Mukherjee R, Menick DR.
    Am J Physiol Heart Circ Physiol; 2015 Jun 01; 308(11):H1391-401. PubMed ID: 25795711
    [Abstract] [Full Text] [Related]

  • 17. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.
    Hsu CP, Huang CY, Wang JS, Sun PC, Shih CC.
    Ann Thorac Surg; 2008 Oct 01; 86(4):1243-9. PubMed ID: 18805169
    [Abstract] [Full Text] [Related]

  • 18. Myocardial infarct expansion and matrix metalloproteinase inhibition.
    Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, Lowry AS, Escobar GP, Lucas DG, Yarbrough WM, Zile MR, Spinale FG.
    Circulation; 2003 Feb 04; 107(4):618-25. PubMed ID: 12566376
    [Abstract] [Full Text] [Related]

  • 19. Cardiac remodeling and failure From molecules to man (Part II).
    Fedak PW, Verma S, Weisel RD, Li RK.
    Cardiovasc Pathol; 2005 Feb 04; 14(2):49-60. PubMed ID: 15780796
    [Abstract] [Full Text] [Related]

  • 20. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
    Li YY, Feldman AM.
    Drugs; 2001 Feb 04; 61(9):1239-52. PubMed ID: 11511020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.